Navigation Links
LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
Date:3/4/2008

ased R&D, increased 39% to $4,591,000 in 2007, compared to $3,301,000 in 2006. The Company launched four products in 2007, including the Pruitt F3 Carotid Shunt (Q1), the Flexcel II Carotid Shunt (Q3), the TT Tortuous Tracker Delivery System (Q4) and the Endofit Uniform TopStent (Q4).

Business Outlook

The Company expects 2008 net sales between $47 million and $48 million. In addition, the Company expects its 2008 operating loss to be comparable to the $4.3 million operating loss posted in 2007. The Company's expectations for future financial performance do not include the impact of any potential acquisitions.

Conference Call Reminder

Management will conduct a conference call at 5:00 p.m. EST today to review the Company's financial results and discuss its business outlook for 2008. The conference call will be broadcast live over the internet. Individuals who are interested in listening to the webcast should log on to the Company's website at http://www.lemaitre.com/investor. The conference call may also be accessed by dialing 866-831-6267 (1-617-213-8857 for international callers) using passcode: 70767653. For interested individuals unable to join the live conference call, a replay will be available on the Company's website.

About LeMaitre Vascular

LeMaitre Vascular is a provider of devices for the treatment of peripheral vascular disease. We develop, manufacture and market disposable and implantable vascular devices to address the needs of vascular surgeons. The Company's devices are used to treat peripheral vascular disease, a condition that we estimate affects more than 20 million people worldwide.

Well-known to vascular surgeons, the Company's diversified product portfolio consists of brand name devices that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome and the Pruitt-Inahara Carotid Shunt. Recent acquis
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. LeMaitre Vascular, Inc. Schedules Fourth Quarter Results and Conference Call
2. LeMaitre Vascular Launches Next-Generation Stent Graft Delivery System
3. LeMaitre Vascular to Participate at Canaccord Adams Inaugural Cardiovascular Conference
4. LeMaitre Vascular Reports Q3 2007 Revenue of $10.1 Million, a 19% Increase
5. LeMaitre Vascular to Participate at CIBC 18th Annual Healthcare Conference
6. LeMaitre Vascular to Start Italian Sales Force
7. Led by Cardiovascular Applications, Double Digit Growth Expected for Catheter Sales
8. Randy Jackson and the American Heart Association Educate Minneapolis Area about the Connection between Type 2 Diabetes and Cardiovascular Disease
9. Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease
10. Curry Ingredient May Cut Cardiovascular Risks
11. Overweight Hispanic children shown to have vascular inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... COLUMBIA, S.C., Dec. 16 Medical travel ... state-of-the-art hospitals in Puerto Rico into its network ... prices substantially lower than those at mainland U.S. ... will offer medical travel assistance and preferred pricing ... who seek treatment at either HIMA San Pablo ...
(Date:12/16/2009)... 16 Quantros, Inc., a leading provider ... solutions for the healthcare industry, announces the creation ... has named software industry veteran Michael Tulloch, MBA, ... work from the company,s new Marlborough, MA office. ... natural one," explains Tulloch. "Quantros has been developing ...
(Date:12/16/2009)... happens when the families of sick and dying hospitalized ... for them? How do pediatricians respond to such personal ... and spirituality help some patients and families cope with ... almost always the families and patients who raise the ... the current issue of Southern Medical Journal , ...
(Date:12/16/2009)... SCHAFFHAUSEN, Switzerland, Dec. 16 Tyco International ... the nomination of Michael E. Daniels for election ... company,s Annual General Meeting on March 10, 2010. ... of the Global Technology Services group of International ... worldwide responsibility for IBM,s Global Services business operations ...
(Date:12/16/2009)... -- While many of the,pharma companies are ... new and inmarket drugs, MarketsandMarkets on the ... various players. These pharma,forecasting solutions are designed ... as phase,III. These have a substantial impact ... entry strategy, manufacturing planning, sales force,promotion, and ...
Breaking Medicine News(10 mins):Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3
... meetings to consider the rising health emergencies and crisis ... days have helped// to promote closer regional cooperation. ... the attempts for development of sustainable programs for Southeast ... of the 8th ASEAN Health Ministers Meeting was the ...
... ahead of Sunday's game, after research has shown that the ... football matches. The game with Ecuador is the first knockout match ... BUPA said: "When people's emotions run high stress levels can shoot ... that history does not repeat itself”. "If England gets ...
... could help reduce muscle damage pain and also be used ... the University of Vermont and colleagues// at Cornell University, New ... processed tart cherry juice blend in a random study on ... asked to either drink a bottle of the cherry juice ...
... infrastructure and provide quality medical education, the government will ... of Rs.15.6 billion, it was announced Thursday. ,The ... Committee on Economic Affairs chaired by Prime Minister Manmohan ... and Kashmir, Uttar Pradesh and Jharkhand. ,The ...
... minor fire broke out in the AII India Institute of ... officials said today. // ,The blaze broke out ... suspected short circuit shortly after 1 a.M., they said., ... blaze was brought under control after around two hours., ...
... research has revealed that PMS, menopause and post natal depression ... // ,Research has revealed that although there are ... pre-menstrual syndrome (PMS), menopause and post natal depression (PND) are ... and psychology at the University of Western Sydney, Jane Ussher ...
Other Medicine News:Health News:Regional Cooperation Promoted in Southeast Asia 2
(Date:12/16/2009)... TechniScan, Inc. (OTC Bulletin Board: TSNI) ... engaged in the development and commercialization of an ... Joe Pepper, PhD, has been appointed to the ... Ken Hungerford commented, "Joe has extensive experience running ... OEC Medical and U-Systems, both of whom compete ...
(Date:12/16/2009)... Inc., a new clinical stage company developing innovative ... on its novel GFPA NMDA receptor modulators, today ... meeting showed that its lead compound GLYX-13 demonstrated ... of the CNS-related side effects seen with other ... also showed that GLYX-13,s antidepressant effects were evident ...
(Date:12/16/2009)... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) is ... Morgan Healthcare Conference at the Westin St. Francis ... 2010. Michael N. Chang, Optimer,s President and Chief ... Time (5:30 p.m. Eastern Time). ,, (Logo: ... this presentation will be accessible on the Investors ...
Breaking Medicine Technology:In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 1DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 2DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America 59892 3Bioidentical Hormones a True Prevention for Breast Cancer 59889 1Bioidentical Hormones a True Prevention for Breast Cancer 59889 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 1Gamida Cell and Cellerix Partner on Feasibility Study 14558 2Gamida Cell and Cellerix Partner on Feasibility Study 14558 3
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced ... clinical trial with LX6171, an oral drug candidate,for ... such as,Alzheimer,s disease, schizophrenia, and vascular dementia. The ... of a new oral-suspension,formulation in healthy elderly subjects ...
... Neurobiological,Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) today ... interim results,for XERECEPT(R) at the Annual Meeting for ... and Chief Executive Officer of NTI, stated, "We,are ... of XERECEPT,and the prospects for this drug, which ...
Other Medicine Technology:Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 2Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 3Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders 4Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 2Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 3Celtic Pharma Provides Update on XERECEPT(R) Clinical Program 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: